Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32


An innovative study design to assess the community effect of interventions to mitigate HIV epidemics using transmission-chain phylodynamics.

Magiorkinis G, Karamitros T, Vasylyeva TI, Williams LD, Mbisa JL, Hatzakis A, Paraskevis D, Friedman SR.

Am J Epidemiol. 2018 Aug 7. doi: 10.1093/aje/kwy160. [Epub ahead of print]


Impact of Interferon-α Receptor-1 Promoter Polymorphisms on the Transcriptome of the Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Karamitros T, Papatheodoridis G, Paraskevis D, Hatzakis A, Mbisa JL, Georgopoulou U, Klenerman P, Magiorkinis G.

Front Immunol. 2018 Apr 16;9:777. doi: 10.3389/fimmu.2018.00777. eCollection 2018.


Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy.

Dunn DT, Stöhr W, Arenas-Pinto A, Tostevin A, Mbisa JL, Paton NI; or the Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy PIVOT Trial Team.

J Clin Virol. 2018 Apr;101:63-65. doi: 10.1016/j.jcv.2018.02.003. Epub 2018 Feb 5.


Molecular epidemiology reveals the role of war in the spread of HIV in Ukraine.

Vasylyeva TI, Liulchuk M, Friedman SR, Sazonova I, Faria NR, Katzourakis A, Babii N, Scherbinska A, Thézé J, Pybus OG, Smyrnov P, Mbisa JL, Paraskevis D, Hatzakis A, Magiorkinis G.

Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1051-1056. doi: 10.1073/pnas.1701447115. Epub 2018 Jan 16.


A European multi-centre External Quality Assessment (EQA) study on phenotypic and genotypic methods used for Herpes Simplex Virus (HSV) drug resistance testing.

Afshar B, Bibby DF, Piorkowska R, Ohemeng-Kumi N, Snoeck R, Andrei G, Gillemot S, Morfin F, Frobert E, Burrel S, Boutolleau D, Crowley B, Mbisa JL.

J Clin Virol. 2017 Nov;96:89-93. doi: 10.1016/j.jcv.2017.10.002. Epub 2017 Oct 6.


Manipulation of both virus- and cell-specific factors is required for robust transient replication of a hepatitis C virus genotype 3a sub-genomic replicon.

Kelly L, Badhan A, Roberts GC, Mbisa JL, Harris M.

J Gen Virol. 2017 Oct 6. doi: 10.1099/jgv.0.000932. [Epub ahead of print]


Efficient and unbiased metagenomic recovery of RNA virus genomes from human plasma samples.

Manso CF, Bibby DF, Mbisa JL.

Sci Rep. 2017 Jun 23;7(1):4173. doi: 10.1038/s41598-017-02239-5.


HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.

El Bouzidi K, White E, Mbisa JL, Sabin CA, Phillips AN, Mackie N, Pozniak AL, Tostevin A, Pillay D, Dunn DT; UK HIV Drug Resistance Database; (UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees; UK HIV Drug Resistance Database (UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees.

J Antimicrob Chemother. 2016 Dec;71(12):3487-3494. Epub 2016 Sep 28.


Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UK.

Cunningham E, Chan YT, Aghaizu A, Bibby DF, Murphy G, Tosswill J, Harris RJ, Myers R, Field N, Delpech V, Cane PA, Gill ON, Mbisa JL.

J Antimicrob Chemother. 2017 Jan;72(1):227-234. Epub 2016 Oct 14.


Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes.

Thomson E, Ip CL, Badhan A, Christiansen MT, Adamson W, Ansari MA, Bibby D, Breuer J, Brown A, Bowden R, Bryant J, Bonsall D, Da Silva Filipe A, Hinds C, Hudson E, Klenerman P, Lythgow K, Mbisa JL, McLauchlan J, Myers R, Piazza P, Roy S, Trebes A, Sreenu VB, Witteveldt J; STOP-HCV Consortium, Barnes E, Simmonds P.

J Clin Microbiol. 2016 Oct;54(10):2470-84. doi: 10.1128/JCM.00330-16. Epub 2016 Jul 6.


De Novo Assembly of Human Herpes Virus Type 1 (HHV-1) Genome, Mining of Non-Canonical Structures and Detection of Novel Drug-Resistance Mutations Using Short- and Long-Read Next Generation Sequencing Technologies.

Karamitros T, Harrison I, Piorkowska R, Katzourakis A, Magiorkinis G, Mbisa JL.

PLoS One. 2016 Jun 16;11(6):e0157600. doi: 10.1371/journal.pone.0157600. eCollection 2016.


Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom.

Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Asboe D, Cane PA; UK HIV Drug Resistance Database.

Clin Infect Dis. 2015 Sep 1;61(5):829-36. doi: 10.1093/cid/civ393. Epub 2015 May 19.


Intrapatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase Inhibitors.

Kayondo JK, Ndembi N, Parry CM, Cane PA, Hué S, Goodall R, Dunn DT, Kaleebu P, Pillay D, Mbisa JL; DART Virology Committee.

AIDS Res Hum Retroviruses. 2015 Jul;31(7):749-56. doi: 10.1089/AID.2015.0035. Epub 2015 Jun 4.


Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK.

El Bouzidi K, White E, Mbisa JL, Phillips A, Mackie N, Pozniak A, Dunn D.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19739. doi: 10.7448/IAS.17.4.19739. eCollection 2014.


HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir.

Sutherland KA, Ghosn J, Gregson J, Mbisa JL, Chaix ML, Cohen Codar I, Delfraissy JF, Delaugerre C, Gupta RK.

J Antimicrob Chemother. 2015 Jan;70(1):243-8. doi: 10.1093/jac/dku365. Epub 2014 Sep 16.


Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genes.

Sutherland KA, Mbisa JL, Ghosn J, Chaix ML, Cohen-Codar I, Hue S, Delfraissy JF, Delaugerre C, Gupta RK.

J Antimicrob Chemother. 2014 Dec;69(12):3340-8. doi: 10.1093/jac/dku296. Epub 2014 Aug 4.


Intercontinental dispersal of HIV-1 subtype B associated with transmission among men who have sex with men in Japan.

Takebe Y, Naito Y, Raghwani J, Fearnhill E, Sano T, Kusagawa S, Mbisa JL, Zhang H, Matano T, Brown AJ, Pybus OG, Dunn D, Kondo M; UK Collaborative Group on HIV Drug Resistance.

J Virol. 2014 Sep 1;88(17):9864-76. doi: 10.1128/JVI.01354-14. Epub 2014 Jun 18.


Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1.

Sutherland KA, Mbisa JL, Cane PA, Pillay D, Parry CM.

J Gen Virol. 2014 Jan;95(Pt 1):190-200. doi: 10.1099/vir.0.055624-0. Epub 2013 Oct 30.


Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.

Dolling DI, Dunn DT, Sutherland KA, Pillay D, Mbisa JL, Parry CM, Post FA, Sabin CA, Cane PA; UK HIV Drug Resistance Database (UKHDRD); UK Collaborative HIV Cohort Study (UK CHIC).

J Antimicrob Chemother. 2013 Oct;68(10):2339-43. doi: 10.1093/jac/dkt199. Epub 2013 May 27.


Dynamics of HIV type 1 recombination following superinfection.

Koning FA, Badhan A, Shaw S, Fisher M, Mbisa JL, Cane PA.

AIDS Res Hum Retroviruses. 2013 Jun;29(6):963-70. doi: 10.1089/AID.2013.0009. Epub 2013 Apr 18.


Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors.

Koning FA, Castro H, Dunn D, Tilston P, Cane PA, Mbisa JL; UK Collaborative Group on HIV Drug Resistance.

J Antimicrob Chemother. 2013 Jun;68(6):1220-36. doi: 10.1093/jac/dkt012. Epub 2013 Feb 5.


Phylodynamic and phylogeographic patterns of the HIV type 1 subtype F1 parenteral epidemic in Romania.

Mbisa JL, Hué S, Buckton AJ, Myers RE, Duiculescu D, Ene L, Oprea C, Tardei G, Rugina S, Mardarescu M, Floch C, Notheis G, Zöhrer B, Cane PA, Pillay D.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1161-6. doi: 10.1089/AID.2011.0390. Epub 2012 May 3.


Molecular and epidemiological characterization of HIV-1 infection networks involving transmitted drug resistance mutations in Northern Greece.

Skoura L, Metallidis S, Buckton AJ, Mbisa JL, Pilalas D, Papadimitriou E, Papoutsi A, Haidich AB, Chrysanthidis T, Tsachouridou O, Antoniadou ZA, Kollaras P, Nikolaidis P, Malisiovas N.

J Antimicrob Chemother. 2011 Dec;66(12):2831-7. doi: 10.1093/jac/dkr386. Epub 2011 Sep 19.


Patterns of resistance development with integrase inhibitors in HIV.

Mbisa JL, Martin SA, Cane PA.

Infect Drug Resist. 2011;4:65-76. doi: 10.2147/IDR.S7775. Epub 2011 Feb 22.


The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.

Mbisa JL, Gupta RK, Kabamba D, Mulenga V, Kalumbi M, Chintu C, Parry CM, Gibb DM, Walker SA, Cane PA, Pillay D.

Retrovirology. 2011 May 11;8:31. doi: 10.1186/1742-4690-8-31.


Intrapatient variation of the respiratory syncytial virus attachment protein gene.

Agoti CN, Mbisa JL, Bett A, Medley GF, Nokes DJ, Cane PA.

J Virol. 2010 Oct;84(19):10425-8. doi: 10.1128/JVI.01181-10. Epub 2010 Jul 21.


APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.

Mbisa JL, Bu W, Pathak VK.

J Virol. 2010 May;84(10):5250-9. doi: 10.1128/JVI.02358-09. Epub 2010 Mar 10.


Real-time PCR analysis of HIV-1 replication post-entry events.

Mbisa JL, Delviks-Frankenberry KA, Thomas JA, Gorelick RJ, Pathak VK.

Methods Mol Biol. 2009;485:55-72. doi: 10.1007/978-1-59745-170-3_5.


Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.

Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, Svarovskaia ES, Brown WL, Mansky LM, Gorelick RJ, Harris RS, Engelman A, Pathak VK.

J Virol. 2007 Jul;81(13):7099-110. Epub 2007 Apr 11.


Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.

Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, Ono A, Freed EO, Hu WS, Pathak VK.

J Biol Chem. 2004 Aug 20;279(34):35822-8. Epub 2004 Jun 20.


Reovirus mu2 protein determines strain-specific differences in the rate of viral inclusion formation in L929 cells.

Mbisa JL, Becker MM, Zou S, Dermody TS, Brown EG.

Virology. 2000 Jun 20;272(1):16-26.

Supplemental Content

Loading ...
Support Center